Investors will be keen to see what strategic goals the newly independent pharmaceutical group Indivior (INDV) publishes alongside its inaugural set of results next week. Not much is known about the entity spun out of consumer goods giant Reckitt Benckiser (RB.) in December.
IC TIP:
Hold
at
178p
Indivior can trace its roots back to 1994, when RB established the Buprenorphine Business Group to focus on developing buprenorphine for patients addicted to opioids. Twenty years later, the group's leading addiction-control product, Suboxone, is still based on that compound.